UCB SA (OTCMKTS:UCBJY) Receives Consensus Rating of “Hold” from Brokerages

UCB SA (OTCMKTS:UCBJY – Get Rating) has received an average rating of “Hold” from the nine brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company.

A number of brokerages have recently commented on UCBJY. Deutsche Bank Aktiengesellschaft cut UCB from a “buy” rating to a “hold” rating in a research note on Monday, January 24th. Morgan Stanley upgraded UCB from an “equal weight” rating to an “overweight” rating in a research note on Thursday, March 3rd. UBS Group cut UCB from a “buy” rating to a “sell” rating in a research note on Thursday, January 13th. Finally, Citigroup lowered UCB from a “buy” rating to a “neutral” rating in a research report on Monday, January 10th.

Shares of UCBJY opened at $53.64 on Friday. UCB has a 52 week low of $44.41 and a 52 week high of $63.94. The stock has a fifty day moving average of $57.83 and a 200-day moving average of $55.66.

The firm also recently declared a dividend, which will be paid on Wednesday, May 18th. Shareholders of record on Monday, May 2nd will be issued a dividend of $0.4413 per share. The ex-dividend date is Friday, April 29th. This represents a yield of 0.74%.

About UCB (Get Rating)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

Further Reading